en <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span style="background:white"><span cambria="" style="font-family:"><span style="color:#7030a0">Aims:</span></span></span></b><b> </b><span cambria="" style="font-family:">Diabetes has been known as a prevalence disorder and the use of common drugs has been faced many issues with multiple limitations. This study aimed to evaluate the use of carvacrol, as a novel agent, for treatment of diabetes<span style="background:white">.</span></span><span style="background:white"><span style="font-family:"Cambria",serif"></span></span></span></span></span><br> <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span style="background:white"><span cambria="" style="font-family:"><span style="color:#7030a0">Materials & Methods:</span></span></span></b> <span cambria="" style="font-family:">In this experimental study, a single dose of streptozotocin (55mg/kg body weight) was used to induce the diabetes in rats. The animals were devided into 5 groups; healthy (negative control), diabetic (positive control), and diabetic given carvacrol in 5-, 10- and 15mg/kg body weight/day of carvacrol in neutral sterile olive oil solution. The levels of malondialdehyde, catalase, superoxide dismutase, and glutathione peroxidase (GPX) activities were evaluated. The levels of IL-1&beta;, IL-6 and TNF-&alpha; expression in liver were assessed<span style="background:white">.</span></span><span style="background:white"><span style="font-family:"Cambria",serif"></span></span></span></span></span><br> <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span style="background:white"><span cambria="" style="font-family:"><span style="color:#7030a0">Findings:</span></span></span></b> <span cambria="" style="font-family:">Streptozotocin increased the levels of malondialdehyde, IL-1&beta;, IL-6 and TNF-&alpha; and also decreased activities of catalase, superoxide dismutase and glutathione peroxidase (p<0.05). Oral administration of carvacrol, especially 15mg/kg body weight/day, decreased the levels of malondialdehyde, IL-1&beta;, IL-6 and TNF-&alpha; and also increased activities of catalase, superoxide dismutase and glutathione peroxidase in comparison to diabetic control (p<0.05)<span style="background:white">.</span></span><span style="background:white"><span style="font-family:"Cambria",serif"></span></span></span></span></span><br> <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span cambria="" style="font-family:"><span style="color:#7030a0">Conclusion:</span></span></b> <span cambria="" style="font-family:">Carvacrol decrease the negative effects of diabetes on inflammation and antioxidant status. <span style="background:white"></span></span></span></span></span><br> &nbsp; Antioxidant Enzymes,Diabetes,Pro-Inflammatory Cytokines, 53 57 http://gmedicine.de/browse.php?a_code=A-10-1-74&slc_lang=en&sid=2 S.A. Tabibzadeh Dezfuli 10031947532846001216 10031947532846001216 No Trauma and Emergency Medicine Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran M. Ehsani 10031947532846001217 10031947532846001217 No Department of Microbiology, Faculty of Basic Sciences, Lahijan Branch, Islamic Azad University (IAU), Lahijan, Iran O. Lakzaei Azar omid.lakzaieazar@yahoo.com 10031947532846001218 10031947532846001218 Yes Young Researchers and Elite Club, Lahijan Branch, Islamic Azad University, Lahijan, Iran